In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) was $24.92 for the day, down -1.15% from the previous closing price of $25.21. In other words, the price has decreased by -$1.15 from its previous closing price. On the day, 2.81 million shares were traded. APLS stock price reached its highest trading level at $25.41 during the session, while it also had its lowest trading level at $24.44.
Ratios:
Our analysis of APLS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.47 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 713.64. For the most recent quarter (mrq), Quick Ratio is recorded 3.16 and its Current Ratio is at 3.77. In the meantime, Its Debt-to-Equity ratio is 3.01 whereas as Long-Term Debt/Eq ratio is at 2.96.
On May 09, 2025, Raymond James Downgraded its rating to Outperform which previously was Strong Buy but kept the price unchanged to $52.
BofA Securities Downgraded its Buy to Neutral on May 09, 2025, while the target price for the stock was maintained at $23.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 30 ’25 when Dunlop A. Sinclair sold 31,092 shares for $22.58 per share. The transaction valued at 702,057 led to the insider holds 33,979 shares of the business.
Dunlop A. Sinclair sold 31,092 shares of APLS for $713,561 on Sep 19 ’25. The Director now owns 68,908 shares after completing the transaction at $22.95 per share. On Sep 19 ’25, another insider, Dunlop A. Sinclair, who serves as the Director of the company, bought 93,276 shares for $22.95 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 3147144704 and an Enterprise Value of 3242129664. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.17 while its Price-to-Book (P/B) ratio in mrq is 20.12. Its current Enterprise Value per Revenue stands at 4.296 whereas that against EBITDA is -17.221.
Stock Price History:
The Beta on a monthly basis for APLS is 0.69, which has changed by -0.06561679 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, APLS has reached a high of $35.72, while it has fallen to a 52-week low of $16.10. The 50-Day Moving Average of the stock is -0.69%, while the 200-Day Moving Average is calculated to be 5.94%.
Shares Statistics:
APLS traded an average of 2.45M shares per day over the past three months and 2461710 shares per day over the past ten days. A total of 126.19M shares are outstanding, with a floating share count of 104.36M. Insiders hold about 17.37% of the company’s shares, while institutions hold 101.11% stake in the company. Shares short for APLS as of 1757894400 were 21758081 with a Short Ratio of 8.87, compared to 1755216000 on 20273707. Therefore, it implies a Short% of Shares Outstanding of 21758081 and a Short% of Float of 22.690001000000002.
Earnings Estimates
At present, 12.0 analysts are actively evaluating the performance of Apellis Pharmaceuticals Inc (APLS) in the stock market.The consensus estimate for the next quarter is -$0.33, with high estimates of $0.22 and low estimates of -$0.61.
Analysts are recommending an EPS of between $0.65 and -$2.29 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$1.11, with 12.0 analysts recommending between $0.45 and -$2.24.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 18 analysts. It ranges from a high estimate of $465M to a low estimate of $178M. As of. The current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $196.83MFor the next quarter, 18 analysts are estimating revenue of $210.65M. There is a high estimate of $283M for the next quarter, whereas the lowest estimate is $182.1M.
A total of 19 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $1.03B, while the lowest revenue estimate was $705.4M, resulting in an average revenue estimate of $925.74M. In the same quarter a year ago, actual revenue was $781.37MBased on 19 analysts’ estimates, the company’s revenue will be $900.81M in the next fiscal year. The high estimate is $1.02B and the low estimate is $757.8M.
